All NEPA doses showed superior overall CR rates compared with PALO ( 87.4 % , 87.6 % , and 89.6 % for NEPA100 , NEPA200 , and NEPA300 , respectively versus 76.5 % PALO ; P < 0.050 ) with the highest NEPA300 dose studied showing an incremental benefit over lower NEPA doses for all efficacy endpoints .